These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36438279)

  • 1. Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.
    Liu J; Cao L; Wu J
    Front Public Health; 2022; 10():1059495. PubMed ID: 36438279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
    Ng-Mak D; Messali A; Huang A; Wang L; Loebel A
    Am J Manag Care; 2019 Jul; 25(14 Suppl):S279-S286. PubMed ID: 31365818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US.
    O'Day K; Rajagopalan K; Meyer K; Pikalov A; Loebel A
    Clinicoecon Outcomes Res; 2013; 5():459-70. PubMed ID: 24049452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia.
    Feng Y; Shi J; Wang L; Zhang X; Tan Y; Zhao J; Ning Y; Xie S; Liu X; Liu Q; Li K; Wang X; Li L; Xu X; Deng W; Luo X; Wang G
    Psychiatry Clin Neurosci; 2020 Jun; 74(6):336-343. PubMed ID: 31823444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
    Awad G; Hassan M; Loebel A; Hsu J; Pikalov A; Rajagopalan K
    BMC Psychiatry; 2014 Feb; 14():53. PubMed ID: 24559217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia.
    Tocco M; Newcomer JW; Mao Y; Pikalov A; Loebel A
    CNS Spectr; 2020 Sep; ():1-11. PubMed ID: 32921337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.
    Higuchi T; Iyo M; Kwon JS; Chou YH; Chen HK; Chen JY; Chen TT; Huang SY; Lee JS; Saeki Y; Tanaka H; Wang TS; Wu BJ; Katoh T; Ishigouoka J
    Asia Pac Psychiatry; 2019 Sep; 11(3):e12354. PubMed ID: 30912222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
    Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
    Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
    Rajagopalan K; Wade S; Meyer N; Loebel A
    Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
    Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
    Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
    Patel PJ; Weidenfeller C; Jones AP; Nilsson J; Hsu J
    Neurol Ther; 2021 Jun; 10(1):121-147. PubMed ID: 33098548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.
    Citrome L; Cucchiaro J; Sarma K; Phillips D; Silva R; Tsuchiya S; Loebel A
    Int Clin Psychopharmacol; 2012 May; 27(3):165-76. PubMed ID: 22395527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
    Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
    Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.
    Jena M; Mishra A; Mishra BR; Nath S; Maiti R
    Psychopharmacology (Berl); 2020 Nov; 237(11):3471-3480. PubMed ID: 32740676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial.
    Jena M; Ranjan R; Mishra BR; Mishra A; Nath S; Sahu P; Meher BR; Srinivasan A; Maiti R
    J Psychiatr Res; 2019 May; 112():1-6. PubMed ID: 30782512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
    Rajagopalan K; Trueman D; Crowe L; Squirrell D; Loebel A
    Pharmacoeconomics; 2016 Jul; 34(7):709-21. PubMed ID: 27067724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom.
    Dymond A; Afonso D; Green W
    BMC Health Serv Res; 2022 Aug; 22(1):1084. PubMed ID: 36002828
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.